Literature DB >> 20369224

Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients.

G Targher1, L Bertolini, M Chonchol, S Rodella, G Zoppini, G Lippi, L Zenari, E Bonora.   

Abstract

AIMS/HYPOTHESIS: Non-alcoholic fatty liver disease (NAFLD) is associated with an increased prevalence of chronic kidney disease (CKD) and retinopathy in patients with type 2 diabetes. Information on this issue is lacking for type 1 diabetes. We evaluated whether NAFLD is associated with increased prevalence of retinopathy and CKD in type 1 diabetic patients.
METHODS: All type 1 diabetic patients (n = 202) who regularly attended our diabetes clinic and did not have any clinical evidence of cirrhosis or other secondary causes of chronic liver disease were studied. Main study measures were detection of NAFLD (by patient history and liver ultrasound), diabetic retinopathy (diagnosed by ophthalmoscopy) and CKD (defined as abnormal albuminuria or estimated GFR of < or =60 ml min(-1) 1.73 m(-2)).
RESULTS: The age- and sex-adjusted prevalence of diabetic retinopathy (53.2 vs 19.8%) and CKD (37.8 vs 9.9%) was markedly higher in patients with NAFLD than in those without (p < 0.0001). In multivariate logistic regression analysis, NAFLD was associated with prevalent retinopathy (adjusted OR 3.31, 95% CI 1.4-7.6, p = 0.005) or CKD (adjusted OR 3.90, 95% CI 1.5-10.1, p = 0.005). These associations were independent of age, sex, diabetes duration, HbA(1c), medication use and presence of the metabolic syndrome. CONCLUSIONS/
INTERPRETATION: Our findings suggest that ultrasound-diagnosed NAFLD is associated, independently of several confounding factors, with a higher prevalence of CKD and retinopathy in type 1 diabetic individuals.

Entities:  

Mesh:

Year:  2010        PMID: 20369224     DOI: 10.1007/s00125-010-1720-1

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  35 in total

1.  Assessing kidney function--measured and estimated glomerular filtration rate.

Authors:  Lesley A Stevens; Josef Coresh; Tom Greene; Andrew S Levey
Journal:  N Engl J Med       Date:  2006-06-08       Impact factor: 91.245

Review 2.  Nonalcoholic fatty liver disease.

Authors:  Leon A Adams; Keith D Lindor
Journal:  Ann Epidemiol       Date:  2007-08-28       Impact factor: 3.797

3.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.

Authors:  Giovanni Targher; Lorenzo Bertolini; Felice Poli; Stefano Rodella; Luca Scala; Roberto Tessari; Luciano Zenari; Giancarlo Falezza
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

4.  The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience.

Authors:  Georgia Pambianco; Tina Costacou; Trevor J Orchard
Journal:  Diabetes Care       Date:  2007-02-15       Impact factor: 19.112

5.  Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Trial.

Authors:  Eric S Kilpatrick; Alan S Rigby; Stephen L Atkin
Journal:  Diabetes Care       Date:  2007-03       Impact factor: 19.112

Review 6.  Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales.

Authors:  C P Wilkinson; Frederick L Ferris; Ronald E Klein; Paul P Lee; Carl David Agardh; Matthew Davis; Diana Dills; Anselm Kampik; R Pararajasegaram; Juan T Verdaguer
Journal:  Ophthalmology       Date:  2003-09       Impact factor: 12.079

7.  Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values.

Authors:  Pouneh Mofrad; Melissa J Contos; Mahmadul Haque; Carol Sargeant; Robert A Fisher; Velimir A Luketic; Richard K Sterling; Mitchell L Shiffman; Richard T Stravitz; Arun J Sanyal
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

Review 8.  Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome.

Authors:  Giovanni Targher; Michel Chonchol; Luca Miele; Giacomo Zoppini; Isabella Pichiri; Michele Muggeo
Journal:  Semin Thromb Hemost       Date:  2009-05-18       Impact factor: 4.180

9.  The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

Authors:  Cynthia J Girman; Thomas Rhodes; Michele Mercuri; Kalevi Pyörälä; John Kjekshus; Terje R Pedersen; Polly A Beere; Antonio M Gotto; Michael Clearfield
Journal:  Am J Cardiol       Date:  2004-01-15       Impact factor: 2.778

10.  Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake.

Authors:  Sabine Thuy; Ruth Ladurner; Valentina Volynets; Silvia Wagner; Stefan Strahl; Alfred Königsrainer; Klaus-Peter Maier; Stephan C Bischoff; Ina Bergheim
Journal:  J Nutr       Date:  2008-08       Impact factor: 4.798

View more
  40 in total

1.  Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis.

Authors:  Giovanni Targher; Lorenzo Bertolini; Stefano Rodella; Giuseppe Lippi; Giacomo Zoppini; Michel Chonchol
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-19       Impact factor: 8.237

Review 2.  Increased risk of cardiovascular disease and chronic kidney disease in NAFLD.

Authors:  Enzo Bonora; Giovanni Targher
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-08       Impact factor: 46.802

Review 3.  Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment.

Authors:  Nathalie C Leite; Cristiane A Villela-Nogueira; Claudia R L Cardoso; Gil F Salles
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 4.  Fatty liver disease in diabetes mellitus.

Authors:  Harikrashna B Bhatt; Robert J Smith
Journal:  Hepatobiliary Surg Nutr       Date:  2015-04       Impact factor: 7.293

5.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

Authors: 
Journal:  Diabetologia       Date:  2016-06       Impact factor: 10.122

6.  Association of Diabetic Nephropathy and Liver Disorders.

Authors:  Usha Sachidananda Adiga; B N Malawadi
Journal:  J Clin Diagn Res       Date:  2016-10-01

7.  Vitamin D status and non-alcoholic fatty liver disease in patients with type 1 diabetes.

Authors:  E Cipponeri; N Vitturi; V Mariano; F Boscari; S Galasso; C Crepaldi; G P Fadini; S Vigili de Kreutzenberg; M C Marescotti; E Iori; F Cavallin; L Sartori; A Baritussio; A Avogaro; D Bruttomesso
Journal:  J Endocrinol Invest       Date:  2019-03-07       Impact factor: 4.256

Review 8.  Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus.

Authors:  Giovanni Targher; Amedeo Lonardo; Christopher D Byrne
Journal:  Nat Rev Endocrinol       Date:  2017-12-29       Impact factor: 43.330

Review 9.  Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence?

Authors:  G Targher; M Chonchol; I Pichiri; G Zoppini
Journal:  J Endocrinol Invest       Date:  2011-03-21       Impact factor: 4.256

10.  Current and future management of diabetic retinopathy: a personalized evidence-based approach.

Authors:  Ryan J Fante; Thomas W Gardner; Jeffrey M Sundstrom
Journal:  Diabetes Manag (Lond)       Date:  2013-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.